Skip to main content
OpenTrials
Completed

NCT Number: NCT03577483

Differential Diagnosis Between Parkinson's Disease and Multiple System Atrophy Using Digital Speech Analysis

Parkinson's disease (PD) is the second most common neurodegenerative disease. Multiple system atrophy (MSA) is a relentlessly progressing rare neurodegenerative disease of unknown etiology. In early stages of the disease, PD and MSA symptoms are very similar, particularly MSA-P where Parkinsonism predominates. The differential diagnosis between MSA-P and PD can be very challenging in early disease stages, while early diagnostic certitude is important for the patient because of the diverging prognosis. Voice disorders are a common early symptom in both diseases and of different origin. The ambition and the originality of this project are to develop a digital voice-based tool for objective discrimination between PD and MSA-P.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson Disease Autonomic Nervous System Diseases Basal Ganglia Diseases Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Hypotension MSA - Multiple System Atrophy Movement Disorders Multiple System Atrophy Nervous System Diseases Neurodegenerative Diseases Parkinsonian Disorders Primary Dysautonomias Shy-Drager Syndrome Synucleinopathies Vascular Diseases

Age range

30 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

Loading trial locations.

About this study

Given the clinical similarity between PD and MSA-P in early disease stages and the severity of the prognosis of MSA-P, it would be very useful to have objective tools to assist in the differential diagnosis between both disorders. Since dysarthria is a common early symptom in both diseases and of different origin, the innovative goal of this project is to use dysarthria, through a digital processing of voice recordings of patients, as a vehicle to distinguish between PD and MSA-P in early disease stages.

The team will build a corpus of voice samples of patients with both diseases and a recent diagnosis (less than 4 years) and controls. This corpus will consist in sustained vowels, utterances of a standard text and spontaneous speech. The recordings will be performed using a high quality digital recorder (H4n) and the DIANA and EVA-2 workstations. DIANA is a state-of-the-art system dedicated to pathological voice recording and analysis.

An electroglottograph (EGG), a non-invasive device, will be also used in conjunction with the recordings to provide the ground truth of glottal opening and closure instants during utterances. The use of an EGG can be very useful given that OGI and GCI provide valuable information about the voice short-time dynamics.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with Parkinson's disease :
  • Diagnosis of idiopathic Parkinson's disease (PD) according to criteria (Hughes et coll., 1992)
  • Patient in early stage of PD : Hoehn&Yahr stage between 1 and 2, and the onset of symptoms ≤ 4 years
  • Patient with or without mild to moderate speech troubles: UPDRS III item 18 ≤ 2
  • Patients with MSA-P (Parkinsonian form) :
  • Diagnosis of Multiple Atrophy System (MSA) Parkinsonian form possible or probable according to Gilman et coll 's criteria (2008)
  • Patient in early stage of MSA-P: score of part IV of the UMSARS (Unified Multiple System Atrophy Rating Scale) ≤ 3 points and the onset of symptoms ≤ 4 years
  • Patient with or without mild to moderate speech troubles: UMSARS II item 2 ≤ 2
  • Controls :
  • Absence of neurologic and oto-rhino-laryngologic disease

Exclusion criteria

  • The deaf and/or mutes
  • Patient with speech troubles which are not related to the MSA or PD
  • Person under safeguard justice, guardianship

Treatment and study plan

voice recordings

Procedure

A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice).

Primary outcomes

  1. Differences between groups in Dysphonia Severity Index (DSI).

    Time frame: Day 1

    DSI will be calculated with the SESANE software (http://www.sqlab.fr/) and with algorithms developed by GeoStat at Inria.

    Evaluation of the rhythm voice

    • Vowels: mean frequency (Hz), variation coefficient (%), jitter factor (%), mean intensity (dB), shimmer factor (%), and noise to harmony ratio (dB).
    • Speech prosody: mean frequency (Hz), variation coefficient (%), minimal frequency (Hz), maximal frequency (Hz), dynamic (Hz), mean duration of speech between two pauses (seconds), total amount of syllables (syllables/s), total amount of pure speech (syllables/s), articulation rate (syllables/s), percentage of pauses (%), percentage of pauses within words (%), time between pauses (s), SPIR index of rhythmicity (words/min), fragmentation of vowels (%), voice onset time (s), stop-consonant spirantization (%).

    Aerodynamic voice parameters will be assessed with the DIANA system (http://www.sqlab.fr/) and algorithms specifically developed by GeoStat at Inria.

  2. Differences between groups in Acoustic Voice Quality Index (AVQI)

    Time frame: Day 1

    AVQI will be calculated with the SESANE software (http://www.sqlab.fr/) and with algorithms developed by GeoStat at Inria.

    Objective measurement of overall voice quality consisted of determining the acoustic parameters for calculating AVQI: smoothed cepstral peak prominence (CPPs) with the computer program "SpeechTool" (James Hillenbrand, Western Michigan University, Kalamazoo, MI, USA) and harmonics-to-noise ratio (HNR), shimmer local, shimmer local dB, general slope of the spectrum (slope) and tilt of the regression line through the spectrum (tilt) with Praat. Te Acoustic Voice Quality Index (AVQI) was calculated according to the regression formula: 2.571 [3.295 - 0.111 (CPPs) - 0.073 (HNR) - 0.213 (shimmer local) + 2.789 (shimmer local dB) - 0.032 (slope) + 0.077 (tilt)].

  3. Differences between groups in oral airflow (dm3/s).

    Time frame: Day 1

    This parameter will be evaluated with the EVA2 system (http://www.sqlab.fr/).

  4. Differences between groups in glottal leakage (cc/s/dB)

    Time frame: Day 1

    This parameter will be evaluated with the EVA2 system (http://www.sqlab.fr/).

  5. Differences between groups in intra-oral pressure (hPa).

    Time frame: Day 1

    This parameter will be evaluated with the EVA2 system (http://www.sqlab.fr/).

Secondary outcomes

  1. Differences between groups in perceptive analysis of dysphonia based on total GRBAS-I scale scores (range 0-18)

    Time frame: Day 1

    The GRBAS-I scale evaluates six items, i.e. G (Grade), R (Roughness), B (Breathiness), A (Asthenicity), S (Strained) and I (Instability)

  2. Differences between groups in perceptive analysis of dysarthria based on French Clinical Dysarthria Battery scores

    Time frame: Day 1

    Sum of all 12 prosody item scores and all 6 phonetic performance item scores; range 0-84.

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Collaborators

  • Institut National de Recherche en Informatique et en Automatique

Registry information

Acronym: Voice4PD-MSA

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Jul 5, 2018
Registry last updated
Nov 28, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.